AFX — Carl Zeiss Meditec AG Balance Sheet
0.000.00%
- €4.00bn
- €4.55bn
- €2.07bn
- 67
- 24
- 37
- 33
Annual balance sheet for Carl Zeiss Meditec AG, fiscal year end - September 30th, EUR millions except per share, conversion factor applied.
R2020 September 30th | 2021 September 30th | 2022 September 30th | 2023 September 30th | 2024 September 30th | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 6.2 | 7.44 | 7.73 | 38.8 | 39.5 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 980 | 1,295 | 1,366 | 1,337 | 617 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 1,291 | 1,604 | 1,792 | 1,912 | 1,212 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 135 | 200 | 236 | 316 | 354 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 2,015 | 2,396 | 2,823 | 3,033 | 3,393 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 298 | 448 | 539 | 562 | 569 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 583 | 737 | 808 | 873 | 1,352 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Other Equity | |||||
| Total Equity | 1,432 | 1,659 | 2,015 | 2,159 | 2,042 |
| Total Liabilities & Shareholders' Equity | 2,015 | 2,396 | 2,823 | 3,033 | 3,393 |
| Total Common Shares Outstanding |